| アブストラクト | Little is known about real-world treatment practices for chronic lymphocytic leukemia (CLL) in Japan. We aimed to assess the time to discontinuation/dose reduction of Bruton tyrosine kinase inhibitors (BTKis) in patients with CLL in a real-world clinical setting in Japan. This was a retrospective observational database study using data from the Medical Data Vision database (from 1 May 2016 to 30 September 2021). Among the 483 patients with CLL who were treated with BTKis, 182 (37.7%) started treatment with a reduced dose of BTKi (lower than the standard dose), 302 (62.5%) experienced at least one dose reduction during the study period, and 123 (25.5%) discontinued BTKi treatment early (for any reason) during the study period. The median time to BTKi discontinuation was 52.3 weeks in 286 patients who started treatment with a standard dose and 57.1 weeks in 182 patients who started treatment with a reduced dose. The use of prophylaxis with anti-infectives was similar during treatment with BTKis and non-BTKis. There was no major difference in the incidence rate of cardiovascular-related adverse events during treatment with BTKis and non-BTKis. This study provides valuable information for future research on the treatment of CLL patients in Japan. |
|---|
| ジャーナル名 | Journal of clinical and experimental hematopathology : JCEH |
|---|
| Pubmed追加日 | 2025/3/31 |
|---|
| 投稿者 | Nishikori, Momoko; Nozaki, Kenji; Hayashi, Yuko; Arita, Yoshifumi; Fujiwara, Masakazu; Iwao, Chikako; Kitagawa, Hiroshi; Maruyama, Dai |
|---|
| 組織名 | Department of Hematology, Kyoto University Hospital, Kyoto, Japan.;Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto,;Japan.;AstraZeneca K.K., Osaka, Japan.;Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation;for Cancer Research, Tokyo, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40159281/ |
|---|
